Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Higham Kessler

Gastroenterology Thornton, CO Medical Doctor

NPI 1003105636 CMS profile 3943038

10001 N. Washington Street, Upper Level, Thornton, CO 80229

Open in the dashboard

General payments

$10,055

441 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Higham Kessler of Thornton, CO is reported in the CMS Open Payments database as having received $10,055 across 441 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $918 46
2024 General $1,667 56
2023 General $1,859 67
2022 General $1,434 68
2021 General $1,729 88
2020 General $943 42
2019 General $1,506 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Higham Kessler
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to James Higham Kessler were reported at $918. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year James Higham Kessler Gastroenterology median Middle half National median
2019 $1,506 $417 $126–$1,100 $163
2020 $943 $224 $74–$624 $114
2021 $1,729 $352 $106–$1,054 $132
2022 $1,434 $448 $129–$1,270 $149
2023 $1,859 $533 $150–$1,390 $160
2024 $1,667 $605 $160–$1,606 $164
2025 $918 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,894 137 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $934 55 payments
  3. Janssen Biotech, Inc. $790 30 payments
  4. Pfizer Inc. $748 29 payments
  5. Gilead Sciences, Inc. $739 40 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $570 29 payments
  7. E.R. Squibb & Sons, L.L.C. $500 6 payments
  8. Celgene Corporation $494 33 payments
  9. Braintree Laboratories, Inc. $358 12 payments
  10. Regeneron Healthcare Solutions, Inc. $285 10 payments
  11. Other $1,743 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,875 437 payments
  2. Education $117 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $63 1 payment
Products named General payments · program years 2019–2025
  1. HUMIRA $1,118 57 payments
  2. ZEPOSIA $994 39 payments
  3. STELARA $721 27 payments
  4. XIFAXAN $716 38 payments
  5. XELJANZ $614 27 payments
  6. RINVOQ $546 29 payments
  7. CREON $386 23 payments
  8. DUPIXENT $337 8 payments
  9. MAVYRET $308 18 payments
  10. LINZESS $279 17 payments
  11. Other $4,838 197 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

267

Median for Gastroenterology: 569

Drug cost

$24,899

Median for Gastroenterology: $104,976

Branded share of claims

75.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 89 $14,694
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 84 $5,867
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 29 $3,621
Omeprazole Generic 47 $524
Pantoprazole Sodium Generic 18 $193

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$35,274

Medicare's payments for the services billed

Medicare patients

211

Average age 71

Services billed

294

113 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 48%
Ischemic heart disease 29%
Diabetes 27%
Chronic kidney disease 25%
Depression 22%
Atrial fibrillation 18%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $249
$249 — —
DUPIXENT
  • Regeneron Pharmaceuticals, Inc. $146
  • Regeneron Healthcare Solutions, Inc. $77
  • GENZYME CORPORATION $19
$242 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $152
$152 — —
VELSIPITY
  • PFIZER INC. $148
$148 — —
SUFLAVE
  • Braintree Laboratories, Inc. $114
$114 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

441 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record